Alkermes’ Antipsychotic Clears US FDA Panel Amid Calls For Broader Professional Education Plan

 
• By Sue Sutter
  
FDA Advisory Committee Feature image
Alkermes proposes to market the drug to treat schizophrenia and bipolar disorder in adults. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers